- Dietary-derived compounds as chemotherapy agents in cancer.
- Epigenomic distortion of transcription factor actions in cancer.
- MicroRNA drivers of cancer progression.
- Translational bioinformatics approaches to reveal novel cancer drivers.
My research goal is to define epigenomic mechanisms that are cancer drivers, and exploit this understanding in diagnostic settings and targeted therapies. Specifically, we focus on understanding how epigenomic events disrupt transcription in solid tumors, notably prostate and breast cancer. To achieve this research goal my group undertakes interdisciplinary approaches. Thus we aim to conceive, design, and interpret experiments that are undertaken both in the wet lab, in Eppendorf tubes, and in the dry lab, at the computer command line.
- 2011 Clinical Sciences Translational Research Fellow, RPCI/University at Buffalo, SUNY
- 2001 Royal Society Travel Award to attend 93rd American Association for Cancer Research meeting, San Francisco
- 2000 Pfizer Travel Award to attend 11th Vitamin D Workshop, Nashville, USA
- 2000 Gillard Exchange Fellowship, British Association for Cancer Research
- 1998 Leukemia Research Fund “Wilsede” Scholarship, Modern Trends in Human Leukaemia, Wilsede, Germany
- 1997 Young Investigator Award, 10th Vitamin D Workshop, Strasbourg, France
- 1990 Faculty Degree Prize, first place in final year, University of the South Bank
- Post-doctoral fellow, 1997, Cedars Sinai Medical Center, UCLA Medical School
- MS, 2016, in Bioinformatics, Johns Hopkins University
- PhD, 1994, in Microbiology, University of Kent
- BSc, 1990, in Applied and Industrial Biology, London South Bank University
Listen to an interview with Moray (published Feb 9, 2017)
Listen to an interview with Moray (published Jan 16, 2014)